Information Provided By:
Fly News Breaks for October 26, 2017
LB, LEA, TRVG, ENT, GSK
Oct 26, 2017 | 10:50 EDT
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at BofA/Merrill with analyst Graham Parry citing increasing headwinds including 2018 margin pressure and consensus reductions from Advair generic erosion, HIV franchise risk from competition, and dividend uncertainty. 2. Global Eagle (ENT) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying Ernst & Young declining to stand for re-appointment increases the chances of an annual filing delay and a potential subsequent delisting by Nasdaq. The analyst cut his price target for the shares to $2 from $3. 3. trivago (TRVG) downgraded to Underperform from Neutral at BofA/Merrill and to Neutral from Buy at Guggenheim. 4. Lear (LEA) downgraded to Neutral from Buy at Guggenheim. 5. L Brands (LB) downgraded to Neutral from Buy at Buckingham with analyst Kelly Halsor saying she believes L Brands' margin recovery is facing headwinds in both brands resulting in incremental pricing investments and promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For GSK;ENT;TRVG;LEA;LB From the Last 2 Days
GSK
Apr 24, 2024 | 07:56 EDT
Due to a rapidly changing epidemiological environment following the end of the COVID-19 pandemic, CureVac and GSK decided to end the Pandemic Preparedness Agreement jointly concluded with the Federal Republic of Germany in April 2022. This decision was made after consultation with the German Federal Ministry of Health and the German Center for Pandemic Vaccines and Therapeutics. The agreement included the provision of production capacity and supply of mRNA-based vaccines in the event of a public health emergency in Germany. Termination will take effect on May 31, 2024, with no further financial obligations. Completion of CureVac's GMP IV manufacturing plant for the production mRNA-based vaccines is unaffected and progressing. Contingent upon regulatory approval, the facility is expected to be certified in the second half of 2024.
GSK
Apr 24, 2024 | 07:29 EDT
CureVac (CVAC) announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A pre-pandemic vaccine candidate developed in collaboration with GSK (GSK). The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans. The monovalent vaccine candidate is based on CureVac's proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen. The combined Phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of an investigational influenza A pre-pandemic vaccine candidate in healthy younger adults aged 18 to 64 and healthy older adults aged 65 to 85. In the initial Phase 1 dose-escalation part of the study, up to five dose levels will be assessed compared to a placebo control. The study will be conducted in the United States. The broad CureVac-GSK infectious disease collaboration was first announced in July 2020. It focuses on applying CureVac's mRNA-technology to the development of new products for infectious disease targets.